(Circulation. 2000;102:2222.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure
From the Cardiomyopathy Program and Cardiovascular Medicine Section, Boston University Medical Center (W.S.C.) and VA Boston Healthcare System (M.T.S.), Boston, Mass; University of Maryland (S.S.G.), Baltimore, Md; University of California (B.H.G.), San Diego; California Pacific Medical Center (E.H.), San Francisco; Johns Hopkins Hospital (J.H.), Baltimore, Md; Cardiology Consultants (S.H.), Little Rock, Ark; Ohio State University (C.V.L.), Columbus; Albert Einstein College of Medicine (T.H.L.), Bronx, NY; University of Pennsylvania Medical Center (E.L.), Philadelphia; University of Michigan Hospital (J.N.), Ann Arbor; Presbyterian University of Pennsylvania Medical Center (D.O.), Philadelphia; West Los Angeles VA Medical Center (B.N.S.), Los Angeles, Calif; and Louisiana Cardiovascular Research Center (W.S.), New Orleans.
Correspondence to Wilson S. Colucci, MD, Cardiovascular Section, Boston University Medical Center, 88 E Newton St, Boston, MA 02118. E-mail wilson.colucci{at}bmc.org
Background—We determined the short-term hemodynamic and clinical effects of levosimendan, a novel calcium-sensitizing agent, in patients with decompensated heart failure.
Methods and Results—One hundred forty-six patients with New York
Heart Association functional class III or IV heart failure (mean left
ventricular ejection fraction 21±1%) who had a
pulmonary capillary wedge pressure 
15 mm Hg and a
cardiac index 
2.5 L · min-1 ·
m-2 were enrolled in a multicenter, double-blind,
placebo-controlled study and randomized 2:1 to intravenous
infusion of levosimendan or placebo. Drug infusions were uptitrated
over 4 hours from an initial infusion rate of 0.1 µg ·
kg-1 · min-1 to a maximum rate of 0.4
µg · kg-1 · min-1 and
maintained at the maximal tolerated infusion rate for an additional 2
hours. Levosimendan caused dose-dependent increases in stroke volume
and cardiac index beginning with the lowest infusion rate and achieving
maximal increases in stroke volume and cardiac index of 28% and 39%,
respectively. Heart rate increased modestly (8%) at the maximal
infusion rate and was not increased at the 2 lowest infusion rates.
Levosimendan caused dose-dependent decreases in pulmonary
capillary wedge, right atrial, pulmonary arterial,
and mean arterial pressures. Levosimendan appeared to
improve dyspnea and fatigue, as assessed by the patient and physician,
and was not associated with a significant increase in adverse
events.
Conclusions—Levosimendan caused rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure. These hemodynamic effects appeared to be accompanied by symptom improvement and were not associated with a significant increase in the number of adverse events. Levosimendan may be of value in the short-term management of patients with decompensated heart failure.
Key Words: heart failure • inotropic agents • vasodilation • calcium
This article has been cited by other articles:
 |
|
 |
|
  K. Jorgensen, O. Bech-Hanssen, E. Houltz, and S.-E. Ricksten Effects of Levosimendan on Left Ventricular Relaxation and Early Filling at Maintained Preload and Afterload Conditions After Aortic Valve Replacement for Aortic Stenosis Circulation, February 26, 2008; 117(8): 1075 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Levy, K. A. Tanaka, and J. M. Bailey Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2008; 3(2008): 77 - 110. [Full Text]
|
|
|
|
 |
|
 I. M. Lang Management of acute and chronic RV dysfunction Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H61 - H67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 629 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Response to Letter Regarding Article, "Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships" Circulation, September 11, 2007; 116(11): e347 - e347. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Takaoka, J. L. Faul, and R. Doyle Current Therapies for Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148. [Abstract] [PDF]
|
|
|
|
|
|
A. Mebazaa, M. S. Nieminen, M. Packer, A. Cohen-Solal, F. X. Kleber, S. J. Pocock, R. Thakkar, R. J. Padley, P. Poder, M. Kivikko, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial JAMA, May 2, 2007; 297(17): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T Parissis, S Adamopoulos, D Farmakis, G Filippatos, I Paraskevaidis, F Panou, E Iliodromitis, and D Th Kremastinos Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart, December 1, 2006; 92(12): 1768 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tokuda, P. W. Grant, H. D. Wolfenden, C. Manganas, W. J. Lyon, and J. S.K. Murala Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery Interactive CardioVascular and Thoracic Surgery, June 1, 2006; 5(3): 322 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Egan, A. J. B. Clarke, S. Williams, A. D. Cole, J. Ayer, S. Jacobe, R. B. Chard, and D. S. Winlaw Levosimendan for Low Cardiac Output: A Pediatric Experience. J Intensive Care Med, May 1, 2006; 21(3): 183 - 187. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Alhashemi Treatment of cardiogenic shock with levosimendan in combination with {beta}-adrenergic antagonists Br. J. Anaesth., November 1, 2005; 95(5): 648 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dernellis and M. Panaretou Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: A Combined Hemodynamic and Doppler Echocardiographic Study Chest, October 1, 2005; 128(4): 2633 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piazza and S. Z. Goldhaber The Acutely Decompensated Right Ventricle: Pathways for Diagnosis and Management Chest, September 1, 2005; 128(3): 1836 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade and F. Zannad Modern management of acute heart failure syndromes Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B3 - B7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Nieminen Pharmacological options for acute heart failure syndromes: current treatments and unmet needs Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B20 - B24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michaels, B. McKeown, M. Kostal, K. T. Vakharia, M. V. Jordan, I. L. Gerber, E. Foster, and K. Chatterjee Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake Circulation, March 29, 2005; 111(12): 1504 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology Eur. Heart J., February 2, 2005; 26(4): 384 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tachibana, H.-J. Cheng, T. Ukai, A. Igawa, Z.-S. Zhang, W. C. Little, and C.-P. Cheng Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H914 - H922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Poder, J. Eha, S. Sundberg, S. Antila, M. Heinpalu, I. Loogna, U. Planken, S. Rantanen, and L. Lehtonen Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study J. Clin. Pharmacol., October 1, 2004; 44(10): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sonntag, S. Sundberg, L. A. Lehtonen, and F. X. Kleber The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2177 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Benlolo, C. Lefoll, V. Katchatouryan, D. Payen, and A. Mebazaa Successful Use of Levosimendan in a Patient with Peripartum Cardiomyopathy Anesth. Analg., March 1, 2004; 98(3): 822 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gegenhuber, T. Mueller, F. Firlinger, K. Lenz, W. Poelz, and M. Haltmayer Time Course of B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP Changes in Patients with Decompensated Heart Failure Clin. Chem., February 1, 2004; 50(2): 454 - 456. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
|
|
B. F. McBride and C. M. White Levosimendan: Implications for Clinicians J. Clin. Pharmacol., October 1, 2003; 43(10): 1071 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward?: Part II: Chronic Inotropic Therapy Circulation, July 29, 2003; 108(4): 492 - 497. [Full Text] [PDF]
|
|
|
|
|
|
D. Arab, A. M. Yahia, and A. I. Qureshi Cardiovascular Manifestations of Acute Intracranial Lesions: Pathophysiology, Manifestations, and Treatment J Intensive Care Med, May 1, 2003; 18(3): 119 - 129. [Abstract] [PDF]
|
|
|
|
|
|
M. Kivikko, L. Lehtonen, W. S. Colucci, and on Behalf of the Study Investigators Sustained Hemodynamic Effects of Intravenous Levosimendan Circulation, January 7, 2003; 107(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bailey, K. A. Tanaka, and J. H. Levy Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2003; 2(2003): 85 - 118. [Full Text]
|
|
|
|
|
|
M. Metra, S. Nodari, A. D'Aloia, C. Muneretto, A. D. Robertson, M. R. Bristow, and L. Dei Cas Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1248 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J V McMurray Heart failure in 10 years time: focus on pharmacological treatment Heart, October 1, 2002; 88(90002): ii40 - 46. [Full Text] [PDF]
|
|
|
|
|
|
A.J.S. Coats Positive inotropy for acute heart failure complicating myocardial infarction Eur. Heart J., September 2, 2002; 23(18): 1405 - 1406. [Full Text] [PDF]
|
|
|
|
|
|
V. S. Moiseyev, P. Poder, N. Andrejevs, M. Y. Ruda, A. P. Golikov, L. B. Lazebnik, Z. D. Kobalava, L. A. Lehtonen, T. Laine, M. S. Nieminen, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur. Heart J., September 2, 2002; 23(18): 1422 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part II Circulation, May 7, 2002; 105(18): 2223 - 2228. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Poole-Wilson Treatment of Acute Heart Failure: Out With the Old, In With the New JAMA, March 27, 2002; 287(12): 1578 - 1580. [Full Text] [PDF]
|
|
|
|
 |
|
 Levosimendan Yields Hemodynamic and Clinical Benefits in Decompensated Heart Failure Journal Watch Cardiology, January 5, 2001; 2001(105): 9 - 9. [Full Text]
|
|